Pharvaris N.V. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
82Pharvaris N.V.'s Business Model
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
About Pharvaris N.V.
Website: https://pharvaris.com
CEO (Chief Executive Officer): Mr. Berndt Axel Edvard Modig CPA, M.B.A.
IPO date: 2021-02-05
Contact
Country: NL
Address: J.H. Oortweg 21
City: Leiden
State: None
Phone: 31 71 203 6410
Zip Code: 2333 CH
Other
CIK: 0001830487
ISIN: NL00150005Y4
CUSIP: N69605108
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
